KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2025)

Rigel Pharmaceuticals has reported Finished Goods over the past 8 years, most recently at $1.8 million for Q3 2025.

  • Quarterly results put Finished Goods at $1.8 million for Q3 2025, down 69.37% from a year ago — trailing twelve months through Sep 2025 was $1.8 million (down 69.37% YoY), and the annual figure for FY2024 was $5.0 million, up 232.49%.
  • Finished Goods for Q3 2025 was $1.8 million at Rigel Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Over the last five years, Finished Goods for RIGL hit a ceiling of $5.8 million in Q3 2024 and a floor of $962000.0 in Q1 2021.
  • Median Finished Goods over the past 5 years was $1.6 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Finished Goods: soared 232.49% in 2024 and later plummeted 69.37% in 2025.
  • Rigel Pharmaceuticals' Finished Goods stood at $1.3 million in 2021, then surged by 45.12% to $1.9 million in 2022, then decreased by 20.8% to $1.5 million in 2023, then soared by 232.49% to $5.0 million in 2024, then tumbled by 64.38% to $1.8 million in 2025.
  • The last three reported values for Finished Goods were $1.8 million (Q3 2025), $2.7 million (Q2 2025), and $3.8 million (Q1 2025) per Business Quant data.